Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 346

1.

Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.

Assel MJ, Ulmert HD, Karnes RJ, Boorjian SA, Hillman DW, Vickers AJ, Klee GG, Lilja H.

Prostate. 2019 Oct 11. doi: 10.1002/pros.23916. [Epub ahead of print]

PMID:
31603253
2.

High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.

Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, DʼAmico AV, Kantoff PW, Bradner JE, Mucci LA, Chavarro JE, Loda M, Brown M.

Nat Commun. 2019 Sep 25;10(1):4358. doi: 10.1038/s41467-019-12298-z.

3.

Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.

Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM.

Clin Cancer Res. 2019 Sep 12. doi: 10.1158/1078-0432.CCR-19-1587. [Epub ahead of print]

PMID:
31515456
4.

Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.

Pan J, Chi C, Qian H, Zhu Y, Shao X, Sha J, Xu F, Wang Y, Karnes RJ, Dong B, Xue W.

Urol Oncol. 2019 Aug 27. pii: S1078-1439(19)30285-6. doi: 10.1016/j.urolonc.2019.07.009. [Epub ahead of print]

PMID:
31466813
5.

Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.

Van den Broeck T, Moris L, Gevaert T, Tosco L, Smeets E, Fishbane N, Liu Y, Helsen C, Margrave J, Buerki C, Davicioni E, Van Poppel H, Everaerts W, Weinmann S, Den R, Davis J, Schaeffer E, Karnes RJ, Claessens F, Joniau S.

Eur Urol Oncol. 2019 Sep;2(5):589-596. doi: 10.1016/j.euo.2018.12.007. Epub 2019 Jan 11.

PMID:
31411980
6.

There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies.

Dell'Oglio P, Stabile A, Soligo M, Brembilla G, Esposito A, Gandaglia G, Fossati N, Bravi CA, Dehò F, De Cobelli F, Montorsi F, Karnes RJ, Briganti A.

Eur Urol Oncol. 2019 Mar 27. pii: S2588-9311(19)30033-1. doi: 10.1016/j.euo.2019.03.002. [Epub ahead of print]

PMID:
31411973
7.

Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.

Ma L, Yan Y, Bai Y, Yang Y, Pan Y, Gang X, Karnes RJ, Zhang J, Lv Q, Wu Q, Huang H.

Theranostics. 2019 Jul 9;9(17):5020-5034. doi: 10.7150/thno.34700. eCollection 2019.

8.

How to guide the selection of patients for trimodality therapy: the case for tumor immune and stromal signature.

Boeri L, Karnes RJ, Montanari E.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S329-S331. doi: 10.21037/tau.2019.05.10. No abstract available.

9.

A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies.

Cheng A, Zhao S, FitzGerald LM, Wright JL, Kolb S, Karnes RJ, Jenkins RB, Davicioni E, Ostrander EA, Feng Z, Fan JB, Dai JY, Stanford JL.

Prostate. 2019 Oct;79(14):1589-1596. doi: 10.1002/pros.23882. Epub 2019 Aug 2.

PMID:
31376183
10.

Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis?

Choo R, Nehra A, Zattoni F, Pagliaro LC, Karnes RJ.

Minerva Urol Nefrol. 2019 Jul 25. doi: 10.23736/S0393-2249.19.03387-3. [Epub ahead of print]

PMID:
31353875
11.

RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.

Bai Y, Yang Y, Yan Y, Zhong J, Blee AM, Pan Y, Ma T, Karnes RJ, Jimenez R, Xu W, Huang H.

Theranostics. 2019 May 24;9(12):3459-3475. doi: 10.7150/thno.33292. eCollection 2019.

12.

Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.

Martini A, Gandaglia G, Karnes RJ, Zaffuto E, Bianchi M, Gontero P, Chlosta P, Gratzke C, Graefen M, Tilki D, Cucchiara V, Mirone V, Kneitz B, Sanchez Salas R, Van Der Poel H, Tombal B, Spahn M, Joniau TS, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT).

Eur Urol Oncol. 2019 Jul;2(4):456-463. doi: 10.1016/j.euo.2018.12.002. Epub 2018 Dec 24.

PMID:
31277783
13.

Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.

Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Quevedo FJ, Cheville JC, Karnes RJ.

Eur Urol Oncol. 2019 Jul;2(4):390-396. doi: 10.1016/j.euo.2018.09.004. Epub 2018 Sep 28.

PMID:
31277775
14.

DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.

Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY.

Clin Cancer Res. 2019 Sep 15;25(18):5608-5622. doi: 10.1158/1078-0432.CCR-18-2387. Epub 2019 Jul 2.

PMID:
31266829
15.

Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.

Stabile A, Dell'Oglio P, Soligo M, De Cobelli F, Gandaglia G, Fossati N, Esposito A, Brembilla G, Karnes RJ, Montorsi F, Briganti A.

Eur Urol Oncol. 2019 Jun 13. pii: S2588-9311(19)30073-2. doi: 10.1016/j.euo.2019.05.006. [Epub ahead of print]

PMID:
31204312
16.

Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy of Localized Prostate Cancer: An Analysis of the ProtecT Trial.

Sharma V, Wymer KM, Borah BJ, Barocas DA, Thompson RH, Karnes RJ, Boorjian SA.

J Urol. 2019 May 21:101097JU0000000000000345. doi: 10.1097/JU.0000000000000345. [Epub ahead of print]

PMID:
31112105
17.

Defining "High Risk" for Men with Localized Prostate Cancer: How Close Can Clinical Parameters Get Us?

Mason RJ, Joniau S, Karnes RJ.

Eur Urol Oncol. 2018 Jun;1(2):149-150. doi: 10.1016/j.euo.2018.04.009. Epub 2018 May 15. No abstract available.

PMID:
31100239
18.

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.

Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, Grubmüller B, Gandaglia G, Briganti A, Karnes RJ.

Eur Urol Oncol. 2018 May;1(1):46-53. doi: 10.1016/j.euo.2018.03.002. Epub 2018 May 15.

PMID:
31100228
19.

Salvage Radical Prostatectomy of Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches.

Gontero P, Marra G, Alessio P, Filippini C, Oderda M, Munoz F, Linares E, Sanchez-Salas R, Challacombe B, Dasgupta P, Goonewardene S, Popert R, Cahill D, Gillatt D, Persad R, Palou J, Joniau S, Piechaud T, Morlacco A, Vidit S, Rouprêt M, De La Taille A, Albisinni S, Gandaglia G, Mottrie A, Joshi S, Fiscus G, Berger A, Aron M, Van Der Poel H, Tilki D, Lawrentschuk N, Murphy DG, Leung G, Davis J, Karnes RJ; Collaborators.

J Urol. 2019 May 10:101097JU0000000000000327. doi: 10.1097/JU.0000000000000327. [Epub ahead of print]

PMID:
31075058
20.

Contemporary Trends in Magnetic Resonance Imaging at the Time of Prostate Biopsy: Results from a Large Private Insurance Database.

Kim SP, Karnes RJ, Mwangi R, Van Houten H, Gross CP, Gershman B, Leapman MS, Shah ND.

Eur Urol Focus. 2019 Apr 29. pii: S2405-4569(19)30102-6. doi: 10.1016/j.euf.2019.03.016. [Epub ahead of print]

PMID:
31047904
21.

Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases.

Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ.

Adv Radiat Oncol. 2019 Feb 19;4(2):314-322. doi: 10.1016/j.adro.2019.02.002. eCollection 2019 Apr-Jun.

22.

Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review.

Calleris G, Marra G, Dalmasso E, Falcone M, Karnes RJ, Morlacco A, Oderda M, Sanchez-Salas R, Soria F, Gontero P.

World J Urol. 2019 Aug;37(8):1469-1483. doi: 10.1007/s00345-019-02749-z. Epub 2019 Apr 6.

PMID:
30955047
24.

Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence.

Wymer KM, Sharma V, Davis BJ, Kwon ED, Mynderse LA, Karnes RJ.

Clin Genitourin Cancer. 2019 Jun;17(3):e536-e540. doi: 10.1016/j.clgc.2019.01.019. Epub 2019 Feb 6. No abstract available.

PMID:
30902522
25.

Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years.

Karnes RJ, Motterle G.

Eur Urol. 2019 Jun;75(6):1035-1036. doi: 10.1016/j.eururo.2019.02.025. Epub 2019 Mar 1. No abstract available.

PMID:
30827693
26.

Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience.

Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Tarrel R, Quevedo FJ, Cheville JC, Karnes RJ.

World J Urol. 2019 Feb 25. doi: 10.1007/s00345-019-02689-8. [Epub ahead of print]

PMID:
30805684
27.

Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study.

Fossati N, Robesti D, Karnes RJ, Soligo M, Boorjian SA, Bossi A, Coraggio G, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Scarcella S, Bartkowiak D, Böhmer D, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A.

Eur Urol. 2019 Oct;76(4):443-449. doi: 10.1016/j.eururo.2019.02.004. Epub 2019 Feb 22.

PMID:
30799187
28.

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.

Cancer Cell. 2019 Mar 18;35(3):401-413.e6. doi: 10.1016/j.ccell.2019.01.008. Epub 2019 Feb 14.

PMID:
30773341
29.

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00036. Epub 2018 Jul 24.

30.

EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.

Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H.

EMBO J. 2019 Mar 1;38(5). pii: e99599. doi: 10.15252/embj.201899599. Epub 2019 Feb 5.

PMID:
30723117
31.

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.

Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ, Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED, Davis BJ, Nathan MA.

Adv Radiat Oncol. 2018 Sep 5;4(1):79-89. doi: 10.1016/j.adro.2018.08.022. eCollection 2019 Jan-Mar.

32.

Comprehensive characterization of perioperative reoperation following radical cystectomy.

Lyon TD, Boorjian SA, Shah PH, Tarrell R, Cheville JC, Frank I, Karnes RJ, Thompson RH, Tollefson MK.

Urol Oncol. 2019 Apr;37(4):292.e11-292.e17. doi: 10.1016/j.urolonc.2018.11.023. Epub 2019 Jan 22.

PMID:
30679081
33.

Impact of time from biopsy to surgery on complications, functional and oncologic outcomes following radical prostatectomy.

Westerman ME, Sharma V, Bailey GC, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Karnes RJ.

Int Braz J Urol. 2019 May-Jun;45(3):468-477. doi: 10.1590/S1677-5538.IBJU.2018.0196.

34.

Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.

Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Quevedo FJ, Cheville JC, Karnes RJ.

BJU Int. 2019 Jun;123(6):1011-1019. doi: 10.1111/bju.14612. Epub 2019 Jan 8.

PMID:
30623554
35.

Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer.

Vasmatzis G, Kosari F, Murphy SJ, Terra S, Kovtun IV, Harris FR, Zarei S, Smadbeck JB, Johnson SH, Gaitatzes AG, Therneau TM, Rangel LJ, Knudson RA, Greipp P, Sukov WR, Knutson DL, Kloft-Nelson SM, Karnes RJ, Cheville JC.

Mayo Clin Proc. 2019 Jan;94(1):27-36. doi: 10.1016/j.mayocp.2018.06.028.

PMID:
30611450
36.

Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancer.

Moschini M, Sharma V, Soligo M, Psutka S, Rangel L, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Karnes RJ.

Scand J Urol. 2018 Oct - Dec;52(5-6):340-348. doi: 10.1080/21681805.2018.1534886. Epub 2019 Jan 2.

PMID:
30600747
37.

Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.

Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):584-590. doi: 10.1158/1055-9965.EPI-18-0667. Epub 2018 Nov 12.

PMID:
30420441
38.

Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.

Gandaglia G, Soligo M, Battaglia A, Muilwijk T, Robesti D, Mazzone E, Barletta F, Fossati N, Moschini M, Bandini M, Joniau S, Karnes RJ, Montorsi F, Briganti A.

Eur Urol. 2019 May;75(5):817-825. doi: 10.1016/j.eururo.2018.10.042. Epub 2018 Nov 5.

PMID:
30409676
39.

A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease.

Lyon TD, Frank I, Sharma V, Shah PH, Tollefson MK, Thompson RH, Karnes RJ, Thapa P, Cheville JC, Boorjian SA.

World J Urol. 2019 Aug;37(8):1605-1613. doi: 10.1007/s00345-018-2551-9. Epub 2018 Nov 3.

PMID:
30392012
40.

Radiotherapy for newly diagnosed oligometastatic prostate cancer.

Boeri L, Sharma V, Karnes RJ.

Lancet. 2018 Dec 1;392(10162):2327-2328. doi: 10.1016/S0140-6736(18)32598-4. Epub 2018 Oct 21. No abstract available.

41.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141.

PMID:
30321406
42.

Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.

Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A.

Eur Urol. 2019 Jan;75(1):176-183. doi: 10.1016/j.eururo.2018.09.009. Epub 2018 Oct 6.

PMID:
30301694
43.

Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy.

Oderda M, Joniau S, Palazzetti A, Falcone M, Melloni G, Van Den Bossche H, Deconinck S, Zattoni F, Karnes RJ, Gontero P.

Eur Urol Focus. 2018 Mar;4(2):288-293. doi: 10.1016/j.euf.2015.12.004. Epub 2015 Dec 24.

PMID:
30205893
44.

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.

Soria F, Pisano F, Gontero P, Palou J, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes JA, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Sylvester R.

World J Urol. 2018 Nov;36(11):1775-1781. doi: 10.1007/s00345-018-2450-0. Epub 2018 Aug 31.

PMID:
30171454
45.

Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort.

Karnes RJ, MacKintosh FR, Morrell CH, Rawson L, Sprenkle PC, Kattan MW, Colicchia M, Neville TB.

Front Oncol. 2018 Aug 6;8:296. doi: 10.3389/fonc.2018.00296. eCollection 2018.

46.

Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. doi: 10.1158/1055-9965.EPI-18-0369. Epub 2018 Aug 14.

PMID:
30108099
47.

Genomic diversity in low-risk disease: present and future.

Sharma V, Karnes RJ.

Nat Rev Urol. 2018 Oct;15(10):594-596. doi: 10.1038/s41585-018-0073-2. No abstract available.

PMID:
30097623
48.

Much ado about robotic versus open radical prostatectomy.

Sharma V, Karnes RJ.

Lancet Oncol. 2018 Aug;19(8):1003-1004. doi: 10.1016/S1470-2045(18)30417-0. Epub 2018 Jul 17. No abstract available.

PMID:
30017350
49.

Temporal trends in venous thromboembolism after radical cystectomy.

Lyon TD, Tollefson MK, Shah PH, Bews K, Frank I, Karnes RJ, Thompson RH, Habermann EB, Boorjian SA.

Urol Oncol. 2018 Aug;36(8):361.e15-361.e21. doi: 10.1016/j.urolonc.2018.05.015. Epub 2018 Jun 7.

PMID:
29885792
50.

Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer.

Bhindi B, Karnes RJ.

Eur Urol. 2018 Oct;74(4):534-535. doi: 10.1016/j.eururo.2018.05.021. Epub 2018 Jun 14. No abstract available.

PMID:
29866462

Supplemental Content

Loading ...
Support Center